Please login to the form below
opioids
This page shows the latest opioids news and features for those working in and with pharma, biotech and healthcare.
FDA clears Sandoz and Pear’s Opioid Use Disorder app
High levels of patients relapsing into opioid dependency is a major part of the problem, particularly in the US, which has reached crisis levels in the country in recent years. ... Corey McCann, President and CEO of Pear Therapeutics, said: “Nearly 50,
Latest news
-
The Final Frontier
Right behind opioids and gabapentin. We don’t need to talk about opioids – everyone knows the destruction they have caused.
-
AcelRX’s potent opioid tablets set to win FDA backing for pain relief
Unlike intravenous-based opioids, Dsuvia, which is already approved in the EU, could allow for a more effective and less invasive pain reliever. ... If given the final OK, the company notes that the drug would be the first new opioid treatment approved
-
Janssen submits esketamine in Europe for treatment resistant depression
However analysts at Evaluate say concerns that the drug might activate opioid receptors in the brain – and therefore be an addiction risk – could lead to the FDA imposing warnings or restrictions
-
FDA awards another non-opioid pain drug breakthrough status
Other non-opioid treatments in the late-stage pipeline are Pfizer and Lilly’s tanezumab and Regeneron and Teva’s fasinumab.. ... prevent more people becoming addicted to opioid painkillers after having been prescribed them by doctors.
-
Regeneron and Teva close gap on rivals with NGF pain drug
therapeutic choices to treat their chronic pain, other than with non-steroidal anti-inflammatory drugs or opioids," said Yancopolous. ... In contrast to opioids, which alter pain perception by targeting opioid receptors, NGF inhibitors block signalling
More from news
Approximately 15 fully matching, plus 121 partially matching documents found.
Latest Intelligence
-
Pharma deals continue to slide
These companies have been running out of cash and have had to do deals to stay alive. Cerecor has sold its kappa opioid receptor antagonist in phase 2 to Janssen ... 74.5 (upfront 65). Cerecor (US). J&J/Janssen (US). Asset acquisition. CERC-501 phase
-
Grünenthal's relentless pursuit of relief
It has the potential to reduce pain without typical opioid therapy side effects and is in development for topical application in hypersensitivity disorders such as Bladder Pain Syndrome or Chronic Stump
-
How digital content helps HCPs curb opioid abuse through better prescribing decisions
In fact, a poll of physicians within our digital community found that 64% believe that doctors have a responsibility to help curb opioid abuse. ... And by delivering information concisely and in an engaging format, this approach is having a measurable
-
Deal Watch March 2016
$110. AstraZeneca/ Kyowa Hakko Kirin. Opioid-induced constipation – Moventig. Licence. $70.
-
Pharma deals in September 2015
Zalviso is a combination drug and device product which uses a patient controlled dispenser to deliver a sub-lingual formulation of sufentanil, an opioid with a high therapeutic index.
More from intelligence
Approximately 1 fully matching, plus 19 partially matching documents found.
Latest appointments
-
Egalet appoints Stan Musial as CFO
s pipeline of abuse-deterrent opioids are nearing phase III.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD) conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018. ... The two-day event succeeded in delivering what IOTOD is well known for: expert
-
IOTOD: Improving Opioid Dependence Outcomes
IOTOD’s future. The IOTOD educational initiative perpetually aims to provide the most up-to-date information in the field of opioid addiction. ... in opioid addiction and gain valuable insight on some of the most controversial topics in the field.
-
"Legal highs" ruling leaves illegal labs laughing
So we are acutely aware of the devastation caused by the opioid epidemic in the US, and the criticism aimed at Purdue, the maker of OxyContin. . ... We have also pitched for agents designed to treat opioid overdose and alcohol abuse. .
-
Research Partnership has published a new Living with Chronic Pain market report for 2016
At least 60% of the patients surveyed are currently prescribed long acting opioids (LAOs).
-
How digital content is helping physicians curb the opioid abuse epidemic
using their state’s Prescription Drug Monitoring Program (PDMP) database before prescribing opioids to a patient. ... topic. And there’s plenty of evidence that this approach works—having a measurable and almost immediate impact on how physicians
More from PMHub
Approximately 1 fully matching, plus 6 partially matching documents found.
Featured jobs
- Business Development Director – Health Education
-
excellent commission
- Account Manager- Healthcare Advertising
-
Negotiable
-
Associate Director
-
£75, 000-90, 000
- Senior Account Executive with progression to Account Manager, Me...
-
Excellent package
- Manager - Immunology, Therapeutic Area Communications & Publ...
-
Competitive Salary Offered
-
Experienced Medical Writers
-
Competitive Salary and Benefits
- Account Executive/ Senior Account Executive
-
competitive Salary Offfered
-
Medical (Scientific) Director
-
£120, 000 benefits
-
Medical Writer
-
Bonus Scheme, PTO &Private Healthcare
-
Senior Account Manager
-
Competitive Salary Offered
-
Business Director
-
Competitive Salary Offered
-
Systematic Reviewer - Oxford
-
Negotiable
-
Account Manager
-
Negotiable
-
Account Manager / Account Director
-
Competative
-
Associate Medical Director
-
Excellent PTO, bonus and 401k package
-
Account Director
-
Competitive Salary Offered
Subscribe to our email news alerts
- FDA takes aim at pharma’s biosimilar-delaying tactics
- Circassia seeks shift to AIM after failing LSE criteria
- Beneluxa: the future of European market access?
- Fishawack acquires Blue Latitude Health
- FDA clears Sandoz and Pear’s Opioid Use Disorder app
- As May delays, industry warns again of ‘no-deal’ Brexit
PMHub
Swordfish Advertising
At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...
Latest intelligence
- Report: Achieving launch excellence in the challenging healthcare markets of today
- Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
- What is blockchain and why should i care - Richard Springham
- Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
- NHS medicines optimisation milestone
- Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...
Quick links
Infographics
